Arlington Trust’s Cytokinetics CYTK Stock Holding History

Arlington Trust’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.79K	Hold	21	–	–	﹤0.01%	683
2026 Q1	$1.38K	Buy	+21	New	+$1.33K	﹤0.01%	695

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arlington Trust's CYTK Position: Q2 2026 in Review

Arlington Trust held its Cytokinetics (CYTK) position steady in Q2 2026 at 21 shares worth $1.79K. The position accounts for ﹤0.01% of the portfolio, ranked #683.

Arlington Trust first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Arlington Trust held 21 shares of Cytokinetics worth $1.79K as of Q2 2026.
Arlington Trust left its Cytokinetics share count unchanged in Q2 2026.
Cytokinetics made up ﹤0.01% of Arlington Trust's portfolio in Q2 2026, its #683 holding.
Arlington Trust first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Arlington Trust's 13F filing for Q2 2026, filed 7 Jul 2026.